Human Drug Compounding Policies and Rules

Why It Matters

Compounding rules directly affect pharmacies, hospitals, and outsourcing facilities’ ability to meet clinical needs while staying compliant, influencing drug supply chains and patient safety nationwide.

Key Takeaways

• 2025 interim policies cover bulk drug use under sections 503A and 503B
• FDA extended 5% out‑of‑state distribution limit enforcement multiple times
• Regular bulk substance lists published to address clinical need gaps
• Guidance issued for specific shortages, e.g., ibuprofen oral suspension
• Proposed rules target drugs difficult to compound under sections 503A/503B

Pulse Analysis

The FDA’s compounding framework has become increasingly granular, with a steady cadence of guidance that clarifies how bulk drug substances may be used by traditional pharmacies and outsourcing facilities. By issuing interim policies for both sections 503A and 503B in early 2025, the agency signals a shift toward more flexible, yet clearly documented, pathways for bulk‑substance compounding. This dual‑track approach helps address persistent drug shortages while preserving the regulatory distinction between patient‑specific compounding and large‑scale manufacturing.

Pharmacies and hospital compounding units must now track multiple bulk‑substance lists that the FDA updates roughly every six months. These lists identify compounds deemed to have a clinical need, guiding facilities on which ingredients they can legally source and compound. Simultaneously, the FDA’s repeated extensions of the 5% out‑of‑state distribution limit give compounding entities additional time to adapt logistics and compliance programs, reducing the risk of abrupt market disruptions. Shortage‑focused guidances—such as the February 2023 ibuprofen oral suspension guidance—demonstrate the agency’s willingness to intervene quickly when specific therapeutic gaps emerge.

Looking ahead, proposed rules targeting drugs that present demonstrable difficulties for compounding suggest a tightening of the permissible drug universe. Stakeholders should anticipate more stringent criteria for bulk‑substance nominations and potentially higher compliance costs. However, the continued publication of detailed FAQs and safety information indicates that the FDA aims to support industry adaptation. Companies that proactively align their compounding operations with the evolving guidance will be better positioned to maintain supply continuity and avoid enforcement actions, ultimately safeguarding patient access to essential therapies.